Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Press Release: “Building the knowledge economy in the world of blood diseases: patients, professionals and Parliamentarians help make the new Europe.”

Aug 30 2011 Posted in Advocacy news

Brussels, 29th August 2011

On the 30th & 31st of August a conference will be hosted in the European Parliament that will demonstrate the leading role haematology will have in securing the future knowledge economy envisaged in the Europe 2020 Strategy.…

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

Dec 13 2023

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition

Nov 18 2020

PRESS RELEASE
Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition

The Hague, Wednesday 18, November, 2020

The field of cell and gene therapy is one of the most…

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

Jun 14 2013

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

Mar 28 2013 Posted in Press releases

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.

Selected EMA news

November 2024New medicines recommended for approval
Eltrombopag Viatris (eltrombopag) – generic
Treatment of primary immune thrombocytopenia and thrombocytopenia associated with chronic hepatitis C (disease in which patients have low levels of blood platelets)

Alhemo (concizumab)
Prevention of bleeding in patients with hemophilia A…

Report on first EHA-SWG Scientific Meeting

Jan 16 2013

The meeting was organized with the main support of the EHA in collaboration with the Hematology Unit of G. Gaslini Children’s Hospital and was sponsored by Novartis and Alexion.

Jean Bernard Lifetime Achievement Award

The Jean Bernard Lifetime Achievement Award was established in 2008 to honor outstanding physicians and scientists for their lifetime contribution to the advancement of hematology.

SWG Educational Activities

EICMLThe 2023 EICML meeting took place in Naples in May 2023. Fifty-five physicians and scientists met at the Palazzo Alabardieri in central Naples to spend two days discussing emerging data and developing collaborations.